News: VBS Vectus Biosystems Announces Successful Convertible Note Issue To Raise $7 Million, page-2

This has been a long time coming and is great news. It has been a very frustrating wait for shareholders with over a year delay, but now things are finally going to happen as they have the cash to complete phase I for VB0004

Phase I determines whether drug is safe to check for efficacy. They had no adverse events when tested with exceptionally high doses on animals, so hopefully this sails through.

Early stage biotechs are always high risk plays, but there is huge upside if successful. Massive addressable space.